164 related articles for article (PubMed ID: 22277677)
1. Inter-individual variability of in vivo CYP2D6 activity in different genotypes.
Chiba K; Kato M; Ito T; Suwa T; Sugiyama Y
Drug Metab Pharmacokinet; 2012; 27(4):405-13. PubMed ID: 22277677
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Malhotra B; Darsey E; Crownover P; Fang J; Glue P
Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
[TBL] [Abstract][Full Text] [Related]
3. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.
Ito T; Kato M; Chiba K; Okazaki O; Sugiyama Y
Drug Metab Pharmacokinet; 2010; 25(3):243-53. PubMed ID: 20610883
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences.
Oishi M; Chiba K; Malhotra B; Suwa T
Drug Metab Pharmacokinet; 2011 Jun; 26(3):236-41. PubMed ID: 21273733
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
8. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Dorne JL; Walton K; Slob W; Renwick AG
Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
[TBL] [Abstract][Full Text] [Related]
9. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
[TBL] [Abstract][Full Text] [Related]
10. Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals.
Jiang F; Yeo CW; Lee SS; Oh MK; Ghim JL; Shon JH; Kim HS; Kim EY; Kim DH; Shin JG
Pharmacogenet Genomics; 2013 Mar; 23(3):175-9. PubMed ID: 23292115
[TBL] [Abstract][Full Text] [Related]
11. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
12. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
[TBL] [Abstract][Full Text] [Related]
13. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.
Brynne N; Svanström C; Aberg-Wistedt A; Hallén B; Bertilsson L
Br J Clin Pharmacol; 1999 Oct; 48(4):553-63. PubMed ID: 10583026
[TBL] [Abstract][Full Text] [Related]
14. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
15. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.
Oishi M; Chiba K; Malhotra B; Suwa T
Drug Metab Dispos; 2010 Sep; 38(9):1456-63. PubMed ID: 20530222
[TBL] [Abstract][Full Text] [Related]
16. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.
Abduljalil K; Frank D; Gaedigk A; Klaassen T; Tomalik-Scharte D; Jetter A; Jaehde U; Kirchheiner J; Fuhr U
Clin Pharmacol Ther; 2010 Nov; 88(5):643-51. PubMed ID: 20881950
[TBL] [Abstract][Full Text] [Related]
17. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
[TBL] [Abstract][Full Text] [Related]
18. From Genotype to Phenotype: Cytochrome P450 2D6-Mediated Drug Clearance in Humans.
Gao J; Tian X; Zhou J; Cui MZ; Zhang HF; Gao N; Wen Q; Qiao HL
Mol Pharm; 2017 Mar; 14(3):649-657. PubMed ID: 28211700
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
20. [Distinguishing CYP2D6 homozygous and heterozygous extensive metabolizers by dextromethorphan phenotyping].
Chen SQ; Cai WM; Wedlund PJ
Yao Xue Xue Bao; 1997 Dec; 32(12):924-7. PubMed ID: 11596190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
